Tag: LEXEO

LEXEO Therapeutics Announces Completion of First Cohort and Dosing in Second Cohort in SUNRISE-FA, a Phase 1/2 Clinical Trial of LX2006 for the Treatment of Friedreich’s Ataxia Cardiomyopathy

Coronary/Structural Heart by 0 comments

LX2006 is the first investigational gene therapy for the treatment of Friedreich’s ataxia cardiomyopathy Initial data from the first two cohorts, including myocardial protein expression and biomarkers measuring serum and cardiac structure and function, expected in the first half of 2024 NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) — LEXEO Therapeutics (LEXEO), […]

Continue Reading →

LEXEO Therapeutics Appoints Micah Zajic as Chief Financial Officer and Paula H. J. Cholmondeley as Board of Directors Audit Committee Chair

Financial by 0 comments

NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) — LEXEO Therapeutics, Inc. (LEXEO), a clinical-stage biotech company advancing a pipeline of adeno-associated virus (AAV)-based gene therapy candidates for cardiovascular and central nervous system (CNS) diseases, today announced the expansion of its leadership team, with the appointment of Micah Zajic as Chief Financial […]

Continue Reading →

LEXEO Therapeutics Announces FDA Clearance of Investigational New Drug Application for LX2006, an AAV-based Gene Therapy Candidate for Friedreich’s Ataxia Cardiomyopathy

Coronary/Structural Heart Regulatory by 0 comments

– Phase 1/2 clinical trial expected to initiate in mid-2022 – – LX2006 is the first clinical-stage program from LEXEO’s cardiovascular pipeline and the third clinical-stage gene therapy candidate across its pipeline – NEW YORK, Feb. 16, 2022 (GLOBE NEWSWIRE) — LEXEO Therapeutics (LEXEO), a clinical-stage gene therapy company advancing a diverse […]

Continue Reading →

LEXEO Therapeutics Expands Cardiac Gene Therapy Pipeline with Acquisition of Stelios Therapeutics and its Gene Therapy Programs for Rare Cardiovascular Diseases

Coronary/Structural Heart Financial by 0 comments

LEXEO obtains exclusive rights to three investigational AAV-mediated gene therapy programs for rare cardiac disorders, all of which have no existing disease-modifying treatments available Strategic acquisition expands LEXEO’s rare cardiac gene therapy pipeline making it one of the most extensive in the field NEW YORK, July 21, 2021 (GLOBE NEWSWIRE) […]

Continue Reading →

LEXEO Therapeutics Announces License Agreement and Consolidation of Comprehensive Pre-clinical Data Package to Support Cardiac Friedreich’s Ataxia Gene Therapy Program (LX2006)

Coronary/Structural Heart by 0 comments

LEXEO completes license of all intellectual property rights and pre-clinical data associated with Adverum Biotechnologies’ investigational Friedreich’s ataxia program Pre-clinical research licensed from academic partners and data from Adverum’s program now consolidated to support the advancement of LX2006; Phase 1 clinical trial expected to initiate in 2021 NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) — LEXEO […]

Continue Reading →